Rising government initiatives and increased funding have emerged as pivotal driver propelling the growth of the market. Governments worldwide are recognizing the transformative potential of omics technologies in revolutionizing healthcare.
For instance, in November 2022, the Texas A&M University System received a USD 1.19 million grant from the National Institutes of Health (NIH) for a multidisciplinary collaboration to study the intricate connections between genomics, nutrition and health.
Moreover, advancements in omics technologies have further propelled the growth of the market. These advancements have led to unprecedented insights into the intricacies of cellular processes, disease mechanisms, and personalized medicine.
As these technologies become more sophisticated and accessible, their application in research, diagnostics, and therapeutic development has expanded, driving the demand for spatial OMICS solutions.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Spatial OMICS market was valued at USD 384.4 million in 2023 and is expected grow at 14.3% CAGR from 2024
The spatial transcriptomics segment accounted for USD 217.3 million, due to its ability to provide a comprehensive understanding of the spatial organization of gene expression within tissues.
North America spatial OMICS industry accounted for USD 167.7 million in 2023 and is anticipated to grow at 14.1% CAGR between 2024
10x Genomics, Akoya Biosciences, Inc., Bio-Techne Corporation, BioSpyder, Inc., Bruker Corporation, Danaher Corporation, Diagenode Diagnostics (Hologic, Inc.), Ionpath, Inc., Millennium Science Pty Ltd., NanoString Technologies, Inc., PerkinElmer, Inc. and S2 Genomics, Inc.